Medicare Program; Adjustment in Payment Amounts for New Technology Intraocular Lenses Furnished by Ambulatory Surgical Centers

Federal RegisterJun 16, 1999

Ask Donna

What actually matters in this document.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

42 CFR Part 416

[HCFA-3831-F]

RIN 0938-AH15

Medicare Program; Adjustment in Payment Amounts for New

Technology Intraocular Lenses Furnished by Ambulatory Surgical Centers

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This final rule establishes a process under which interested

parties may request a review of whether the current Medicare payment

amount for intraocular lenses furnished by participating ambulatory

surgical centers is appropriate for a class of new technology

intraocular lenses. This rule implements section 141(b) of the Social

Security Act Amendments of 1994, which requires us to develop and

implement this process.

This rule also serves as the initial notice to those wishing to

submit requests for review of the appropriateness of the payment amount

with respect to a particular intraocular lens, in accordance with

Sec. 416.195 of this rule.

DATES: Effective date: These regulations are effective on July 16,

1999.

Applicability date: We will accept requests for review under this

part 416, subpart F, until September 14, 1999.

FOR FURTHER INFORMATION CONTACT: Claude Mone, (410) 786-5666.

SUPPLEMENTARY INFORMATION: Copies: To order copies of the Federal

Register containing this document, send your request to: New Orders,

Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250-

7954. Specify the date of the issue requested and enclose a check or

money order payable to the Superintendent of Documents, or enclose your

Visa or Master Card number and expiration date. Credit card orders can

also be placed by calling the

[[Page 32199]]

order desk at (202) 512-1800 or by faxing to (202) 512-2250. The cost

for each copy is $8. As an alternative, you can view and photocopy the

Federal Register document at most libraries designated as Federal

Depository Libraries and at many other public and academic libraries

throughout the country that receive the Federal Register.

I. Background

A. Payment for Ambulatory Surgical Center Facility Services

Section 1832(a)(2)(F)(i) of the Social Security Act (the Act)

provides that the scope of benefits under the Medicare supplementary

medical insurance (Part B) program includes certain services furnished

in connection with surgical procedures that are performed in an

ambulatory surgical center (ASC). To participate in the Medicare

program as an ASC, a facility must meet the standards specified under

section 1832(a)(2)(F)(i) of the Act and in our regulations at 42 CFR

part 416. In addition, our regulations at 42 CFR part 416 contain the

coverage and payment rules for services furnished by participating

ASCs.

Section 1833(i)(2)(A) of the Act authorizes us to pay ASCs a

prospectively-determined rate for facility services. ``Facility

services'' includes services that are furnished in conjunction with

covered surgical procedures performed in an ASC. Section 416.61 of our

regulations sets forth included and excluded facility services. ASC

payment rates represent our estimate of a fair fee that takes into

account the costs incurred by ASCs generally in furnishing facility

services in connection with performing a surgical procedure. ASC

payment rates do not include physicians' fees and other medical items

and services, such as laboratory services or prosthetic devices, for

which separate payment may be authorized under other provisions of the

Medicare program. However, an intraocular lens (IOL) is included as an

ASC facility service under section 1833(i)(2)(A)(iii) of the Act.

Payment for ASC facility services is subject to the usual Medicare

Part B deductible and coinsurance requirements. Therefore,

participating ASCs are paid 80 percent of the prospectively-determined

rate adjusted for regional wage variations. The beneficiary pays a

coinsurance amount equal to 20 percent of the wage-adjusted ASC

facility fee.

Currently, the Medicare program pays an ASC facility fee for

approximately 2,300 surgical procedures performed in an ASC. These

surgical procedures are identified by codes established by the American

Medical Association's Current Procedural Terminology (CPT). We assign

to each procedure one of eight standard payment rates. Collectively,

the procedures assigned a particular payment rate constitute an ASC

payment group. The current payment group rates follow:

Group 1--$312 Group 5--$674

Group 2--$419 Group 6--$785

Group 3--$479 Group 7--$935

Group 4--$591 Group 8--$923

This is further discussed in our September 4, 1997 proposed rule,

``Medicare Program; Adjustment in Payment Amounts for New Technology

Intraocular Lenses'' (62 FR 46699).

B. Payment for Intraocular Lenses Furnished in an Ambulatory Surgical

Center

In the proposed rule, we explained that at the inception of the ASC

benefit on September 7, 1982, Medicare paid 80 percent of the

reasonable charge for IOLs supplied for insertion concurrent with or

following cataract surgery performed in an ASC. Subsequently, the

statute was amended to mandate that we include payment for an IOL

furnished by an ASC for insertion during or following cataract surgery

as part of the ASC facility fee rather than paying for the IOL

separately. Payment included in the facility fee for an IOL must be

reasonable and related to the cost of acquiring the class of IOL

involved.

Thus, for services furnished beginning March 12, 1990, which was

the effective date of the final notice published in the Federal

Register on February 8, 1990, entitled ``Revision of Ambulatory Surgery

Center Payment Rate Methodology'' (55 FR 4526), Medicare included

payment for an IOL in payment group 6 and payment group 8, the two

payment groups that include IOL insertion procedures. The Physicians'

Current Procedural Terminology (CPT) codes for groups 6 and 8 and their

descriptors follow:

Payment group 6:

CPT code 66985........... Insertion of intraocular lens prosthesis

(secondary implant), not associated with

concurrent cataract removal.

CPT code 66986........... Exchange of intraocular lens. (This CPT

code was first listed in CPT 1992; we

added it to the ASC list effective

January 30, 1992.)

Payment group 8:

CPT code 66983........... Intracapsular cataract extraction with

insertion of intraocular lens prosthesis

(one stage procedure).

CPT code 66984........... Extracapsular cataract removal with

insertion of intraocular lens prosthesis

(one stage procedure), manual or

mechanical technique (for example,

irrigation and aspiration or

phacoemulsification).

Section 4151(c)(3) of the Omnibus Budget Reconciliation Act of 1990

(OBRA 1990) (Public Law 101-508), enacted on November 5, 1990, froze

the IOL payment amount at $200 for IOLs furnished by ASCs in

conjunction with surgery performed during the period beginning November

5, 1990 and ending December 31, 1992. We continued paying an IOL

allowance of $200 from January 1, 1993 through December 31, 1993.

Section 13533 of the Omnibus Budget Reconciliation Act of 1993

(OBRA 1993) (Public Law 103-66), enacted on August 10, 1993, mandated

that payment for an IOL furnished by an ASC be equal to $150 beginning

January 1, 1994 through December 31, 1998.

In a proposed rule in the June 12, 1998 Federal Register (63 FR

32290) entitled ``Medicare Program; Update of Ratesetting Methodology,

Payment Rates, Payment Policies, and the List of Covered Surgical

Procedures for Ambulatory Surgical Centers Effective October 1, 1998,''

we proposed new payment rates and an ambulatory payment classification

(APC) system based on facility costs and procedure charges collected in

a 1994 survey of ASCs. In that proposed rule, we stated that the 1994

survey data revealed that the current IOL allowance of $150 is higher

than the cost of acquiring the lens. The survey data indicated that the

weighted mean lens cost was $100, and the weighted median cost was $97.

We

[[Page 32200]]

stated that before December 31, 1998, we would propose a revised

payment rate for lens insertion procedures to include an IOL allowance

that is reasonable and related to the cost of the lens. However, we

subsequently issued notices in the Federal Register on October 1, 1998

(63 FR 52663) and November 13, 1998 (63 FR 63430) that extended the

comment period on the proposed rule and announced that a final rule

would be issued as soon as possible after January 1, 2000.

II. Provisions of the Proposed Regulations

A. Requirement for Review of Payment for New Technology Intraocular

Lenses

On October 31, 1994, the Social Security Act Amendments of 1994

(SSAA 1994) (Public Law 103-432) were enacted. Section 141(b) of SSAA

1994 requires us, not later than 1 year after the date of enactment

(that is, by October 31, 1995), to develop and implement a process

under which interested parties may request, with respect to a class of

new technology IOLs, a review of the appropriateness of the payment

amount provided for IOLs furnished by ASCs under section

1833(i)(2)(A)(iii) of the Act. Since January 1, 1994, the payment

amount for IOLs furnished by ASCs under section 1833(i)(2)(A)(iii) of

the Act has been $150.

Section 141(b)(1) of SSAA 1994 stipulates that an IOL may not be

treated as a new technology IOL unless it has been approved by the Food

and Drug Administration (FDA). Section 141(b)(2) of SSAA 1994 requires

that, in determining whether to provide a payment adjustment, we take

into account whether use of the IOL is likely to result in reduced risk

of intraoperative or postoperative complication or trauma, accelerated

postoperative recovery, reduced induced astigmatism, improved

postoperative visual acuity, more stable postoperative vision, or any

other comparable clinical advantages.

Section 141(b)(3) of SSAA 1994 requires that we publish at least

annually a list of the requests received for review of the

appropriateness of the IOL payment amount with respect to a new

technology IOL. We must provide a 30-day comment period on the IOLs

that are the subject of the requests for review. Within 90 days of the

close of the comment period, we must publish a notice of the

determinations made with respect to the appropriateness of the IOL

payment amount for the IOLs for which a review was requested. Any

adjustment of the IOL payment amount (or payment limit) for a

particular IOL or class of IOLs that we determine is warranted would be

effective not later than 30 days following publication of the final

notice of our determination.

Implementation of section 141(b) of SSAA 1994 requires three

principal policy decisions:

Identification of a class or classes of new technology

IOLs.

Determination of whether the current IOL payment amount is

appropriate for an IOL identified as belonging to a class of new

technology IOLs.

Identification of the payment adjustment to be applied if

the current payment amount is found to be inappropriate.

B. Identification of a Class of New Technology Intraocular Lenses

1. Distinguishing Among Classes of Intraocular Lenses

In order to prepare the final notice entitled ``Revision of

Ambulatory Surgery Center Payment Rate Methodology'' (55 FR 4526) that

was published in the Federal Register on February 8, 1990, we sought

supporting documentation that would justify pricing IOLs according to

IOL type or ``class,'' and that would establish the basis for

distinguishing among different types of IOLs, such as placement of the

IOL within the eye, either as anterior chamber or posterior chamber

IOLs; or the style of the IOL, either single-piece or multi-piece; or

characterization of the IOL as ``advanced technology.''

On February 22, 1989, the FDA advised us in a letter that its

premarket approval review process determined whether IOLs were ``safe

and effective'' not by comparing IOLs with one another, but by

comparing them with a set of historical IOL data known collectively as

the ``grid.'' The FDA noted that no additional labeling or advertising

claims of the superiority of one IOL (or type of IOL) over another had

been approved at that time; that is, medical benefits of one IOL or

type of IOL over another had not been proven in the studies that were

submitted to the FDA. There were no across-the-board differences in the

indications and contraindications or in the warnings sections of the

package insert that would imply across-the-board medical benefits for

one IOL or type of IOL over another.

The studies that were submitted to HCFA at that time failed to

yield conclusive evidence of specific clinical conditions or

indications that required or influenced the use of one IOL over

another, nor did HCFA find justification for a differentiated price

structure based on IOL type. We therefore determined that a $200

payment amount was both reasonable and related to the costs incurred by

ASCs to acquire IOLs available at that time.

2. Criterion To Define a Class of New Technology Intraocular Lenses

There still is no universally accepted definition of what

constitutes a ``class of new technology intraocular lenses.'' Section

141(b) of SSAA 1994 does not define new technology IOLs other than to

specify that an IOL may not be treated as a new technology IOL unless

it has been approved by the FDA. We must therefore first define the

characteristics that distinguish a ``new technology'' IOL from other

IOLs in order to comply with section 141(b) of SSAA 1994.

Section 141(b) of SSAA 1994 requires that we take clinical outcomes

such as ``reduced risk of intraoperative or postoperative complication

or trauma'' and ``reduced induced astigmatism'' into account in

determining whether to provide a payment adjustment with respect to a

particular IOL. Because they are identified with such specificity, we

infer that the clinical outcomes listed in the law are intended to

characterize IOLs that belong to a ``class of new technology

intraocular lenses,'' the use of which not only produces the specified

clinical outcomes, but does so to a greater degree than other IOLs. We

submit that the latter consideration is crucial because of the abundant

evidence that demonstrates that IOLs have attained a level of technical

sophistication, clinical success, and patient satisfaction that exceeds

that of the more than 1 million IOLs implanted during clinical trials

conducted between 1978 and 1982. (An analysis of the 1978 through 1982

clinical trial data forms the FDA's ``grid,'' the historical control

group against which newer IOLs are measured.) To illustrate, 93 percent

and 96.8 percent of patients in trials of two IOLs that were approved

in 1994 achieved visual acuity of \20/40\ or better, compared to 88

percent of patients in the historical control group. The ``best

cases,'' those without any preoperative ocular pathology or macular

degeneration at any time, achieved visual acuity of \20/40\ or better

in 97 percent and 99.5 percent of the patients in the two newer trials,

compared to 94 percent of the control group grid patients. The high

level of improved vision and the low rate of adverse effects already

attainable using currently available IOLs seem to leave little room for

substantive improvements in the areas listed as desirable outcomes in

SSAA 1994. At issue, then, is how to

[[Page 32201]]

recognize IOLs that exceed the already superior levels of performance

of IOLs readily accessible in the current market to such an extent that

they warrant being recognized as belonging to a separate and distinct

class of IOLs. We proposed that the criterion for identifying an IOL to

be treated as a new technology IOL be that all claims of the IOL's

clinical advantages and superiority over existing IOLs must have been

approved by the FDA for labeling and advertising purposes. An

explanation of the reasons for relying on the FDA's determination is

explained in the proposed rule (62 FR 46700 through 46701). We received

favorable public comments on the proposal and adopted them in this

final rule.

3. Five-Year Limit on Subsets of ``New Technology''

We proposed to impose certain constraints on payment adjustments

that result from the process that is the subject of this rule. For

instance, we did not believe that all IOLs that could satisfy the

overall criteria of ``new technology'' in the proposed rule would

necessarily be of the same type or category. Rather, based on our

assessment of the kinds of IOLs that are currently in clinical trials,

we believe ``new technology'' IOLs could logically be grouped into

smaller subsets of ``new technology,'' each of which is defined or

identified by a common salient feature or characteristic, such as

fabrication from the same material, or being multifocal in design, or

designed to correct astigmatism.

For payment purposes, after we accept an IOL as satisfying the

criterion for belonging to a ``class of new technology lenses,'' we

proposed to assign that IOL to a subset of IOLs with which it shares a

common feature that distinguishes it from other ``new technology''

IOLs. We further proposed to set the lifespan of each subset of ``new

technology'' IOLs at 5 years. That is, beginning the sixth year

following our initial recognition of a ``new technology'' subset, the

new technology attribute that the IOLs in the subset have in common

would cease to be considered a characteristic of ``new technology,''

and the Medicare payment adjustment for IOLs in that subset would be

discontinued. We would not have considered for payment adjustment any

other IOLs whose primary distinguishing feature was that attribute. For

IOLs approved at the beginning of the fifth year of the subset term,

Medicare would have paid any ``new technology'' adjustment for 1 year

only.

We proposed a 5-year limit because defining a ``new technology''

characteristic as ``new'' for fewer than 5 years did not seem fair to

manufacturers whose model(s) of the new technology IOL may receive FDA

approval sometime after the original IOL that opened the subset within

the class of ``new technology'' IOLs receives its premarket approval.

But to define a ``new technology'' characteristic as ``new'' for more

than 5 years seemed to impose an unnecessary and unwarranted drain on

the Medicare trust fund, given the natural course of market forces that

have repeatedly succeeded in reducing IOL costs in a few years

following introduction of a modification or innovation in design or

material.

C. Appropriateness of Payment Amount

SSAA 1994 requires us to review the appropriateness of the current

IOL payment amount with respect to a class of new technology IOLs.

Because SSAA 1994 itself does not provide explicit guidance on the

standard for judging the appropriateness of the current IOL payment

amount, we looked to section 1833(i)(2)(A)(iii) of the Act, which

requires that the IOL payment amount included in the ASC facility fee

be reasonable and related to the cost of acquiring the class of IOL

involved. Therefore, after we determine that an IOL meets the criterion

that qualifies it to be treated as a new technology IOL under the

process in this rule, we reasoned that we must next determine if the

current IOL payment amount is reasonable and related to the cost of

acquiring that IOL. We have reconsidered this issue in light of the

public comments, which are addressed later in this final rule.

We also proposed that in order to determine IOL acquisition costs,

we would be required to survey purchasers and audit invoices. The OIG

conducted such a survey in preparing its 1994 report entitled

Acquisition Costs of Prosthetic Intraocular Lenses, OEI-05-92-01030.

(Copies can be obtained from the Office of Inspector General,

Department of Health and Human Services, (312) 353-4124.) The OIG found

that when IOL payments were fixed at $200, ASCs could acquire and were

acquiring IOLs for an average of $126 in 1991 and $112 in 1992. This

does not take into account discounts available to the majority of

purchasers because the financial arrangements took many forms, only a

few of which were straightforward rebates or price reductions. The OIG

also discovered that the newest type of IOL available at the time of

its review (a foldable, ultraviolet-absorbing, silicone IOL) was

obtainable within relatively the same price range as other IOLs in the

study (from $75 to $475 for the foldable IOLs, compared to a range of

$30 to $450 for rigid IOLs). The OIG determined that ASCs were buying

foldable IOLs for $125 or less, at a time when the Medicare IOL payment

amount was $200.

We received several public comments concerning this proposal. We

have reconsidered the process for adjusting payments for new technology

IOLs in light of these comments, and we are no longer requiring the

submission of data concerning the costs of acquiring the new technology

IOL in order to determine the appropriateness of the IOL payment

amount. Rather, as we discuss in the Analysis and Responses to Public

Comments section of this rule, once an IOL is determined to be a new

technology IOL, we will pay a flat premium in the amount of $50, over

and above the payment allowance already included in the ASC facility

fee for a standard IOL.

D. Payment Adjustment When Current Payment Amount Is Inappropriate

The final step in the process that was the subject of the proposed

rule involved determining the amount of a payment adjustment if we find

that the current IOL payment amount is inappropriate. Among the factors

that we proposed in order to determine the amount of the adjustment to

be made if the current IOL allowance was found to be inappropriate with

respect to the acquisition cost of the particular IOL were the

following:

Market projections based on anticipated clinical

indications of need for the IOL and the percent of the Medicare

population expected to present that need on an annual basis.

Additional incremental costs incurred to manufacture a new

technology IOL relative to the cost of manufacturing other IOLs, such

as the cost attributable to using a more sophisticated piece of

machinery or the cost of fabricating a new IOL material.

Additional costs incurred to conduct clinical trials that

document for FDA approval the clinical superiority of the IOL relative

to the costs incurred to conduct clinical trials for other IOLs.

Research and development costs incurred that exceed those

associated with other IOLs approved by the FDA.

Current and historical pricing, sales volume, and

revenues.

A reasonable rate of return and profit based on the

manufacturer's investment in the IOL.

[[Page 32202]]

We considered other options for determining the amount of an

adjustment to be made if the current payment amount was found to be

inappropriate for an IOL being reviewed under the provisions in this

rule including--

Application of a single flat, across-the-board percentage

increase to the IOL payment amount for every IOL that we determined

satisfied the criteria defining a ``new technology'' IOL.

The percent of the IOL industry's investment in research

and development that ultimately leads to innovations in IOLs.

The percentage of sales attributable to an IOL for which a

review was requested.

We rejected these options at that time, primarily because we

believed they were inconsistent with the overall statutory mandate that

payment be reasonable and related to the cost of acquiring an IOL. We

received public comments concerning this position, and one commenter

expressly disagreed with our interpretation of the statute. We have

reconsidered our position in light of this comment. Further discussion

can be found in the Analysis of and Responses to Public Comments

section.

E. Implementation of the Payment Adjustment

1. Two-Year Limit on Payment Adjustment

A related issue pertains to the appropriate length of time the

adjusted payment amount would be allowed by Medicare for a particular

``new technology'' IOL. We proposed to allow a single IOL the benefit

of any payment adjustment determined to be appropriate for a period of

2 years following the review process in this rule. At the conclusion of

the 2-year payment adjustment period, Medicare payment for the IOL

would then revert to the standard payment rate for IOLs furnished by an

ASC that is in effect at that time.

Supporting a 2-year payment limit is the OIG's 1994 report

(Acquisition Costs of Prosthetic Intraocular Lenses, OEI-05-92-01030),

which found a decrease in IOL prices generally over a 2-year period

ranging from 11 to 14 percent in various settings. We assume this

decrease is attributable to technology diffusion and the associated

development of similar lenses by competing firms. We believe a

desirable new technology IOL with demonstrated clinical superiority

would be subject to equivalent conditions, and thus experience a

similar drop in acquisition cost over a 2-year period. However, after

considering the public comments on this issue, we have developed an

alternative to this 2-year payment adjustment. See the Analysis of and

Responses to Public Comments section for further discussion.

2. Operational Payment Principles

The payment adjustments we publish in the Federal Register would be

implemented prospectively, effective 30 days from the date of their

publication. This implementation date of a payment adjustment is

required under section 141(b) of SSAA 1994.

We proposed to apply the same payment adjustment amount established

for the first IOL or IOLs approved within a new technology subset to

all IOLs that we subsequently accept as satisfying the criteria for

``new technology'' that are assigned to the same subset. If a new

technology IOL were to qualify under more than one subset of

technology, and the subsets had different payment rates, the IOL would

be paid for at the higher (or highest) applicable rate.

We expect that more than one manufacturer would be working to

develop IOLs that rely on the same or similar technology that defines

``new technology'' under the provisions of this rule. If we were to

make a payment adjustment under the provisions in this rule, the

payment adjustment amount would have been based on information

regarding IOL production, acquisition costs, and IOL benefits that is

submitted by the manufacturer or manufacturers that first request

review for a particular type of new technology IOLs. Manufacturers

would have had 3 years during which to submit requests for review of

equivalent IOLs approved by the FDA that were in a ``new technology''

subset already approved by us and still benefit from the full 2-year

payment adjustment term. Requests for review of an IOL submitted during

the third year of a technology's designation as ``new'' would only have

had the benefit of a payment adjustment for 1 year. Again, we have

modified this proposal. Further discussion can be found in the Analysis

of and Responses to Public Comments section.

If an interested party wants an IOL to be considered for a payment

adjustment under section 141(b) of SSAA 1994, that interested party

must request a review in accordance with the process in this final

rule.

We will assign codes to be used to bill for IOLs that qualify for

the payment adjustment. The list of these IOLs, with the appropriate

billing code, will be published periodically in the Federal Register.

Billing for any other IOLs using ``new technology'' billing codes may

constitute fraud.

F. Review and Adjustment Process

In this section of the proposed rule, we described the process that

we intended to implement in order to determine the appropriateness of

IOL pricing as required under section 141(b) of SSAA 1994. The process,

which was designed to be repeated annually on a 365-day cycle, would

have involved publishing a series of Federal Register notices with

built-in comment periods and allowance of time to review the

appropriateness of payment amounts for new technology IOLs. However,

since we are revising this review process, we believe we can shorten

the timeframe to accomplish this to 180 days. For a further discussion

of this issue see the Analysis of and Responses to Public Comments

section.

G. Requirements for Content of a Request To Review

In the proposed rule, interested parties requesting a review of the

IOL payment amount with respect to a particular IOL would have been

required to submit the following: identification of the individual IOL

under consideration as a ``new technology'' IOL for which a payment

review is requested, including the name of the manufacturer, model

number, trade name, and the date the FDA granted premarket approval for

the IOL; a copy of the FDA's summary of safety and effectiveness; a

copy of the labeling claims of specific clinical advantages approved by

the FDA; reports of modifications made after FDA approval; development

and manufacturing costs of the ``new technology'' IOL relative to the

costs of manufacturing other approved IOLs; the costs of conducting

clinical trials for the IOL in question relative to the costs of

conducting clinical trials for other approved IOLs; indications and

contraindications for use; epidemiological data indicating demand for

the IOL; sales price, sales history, and revenues, and prices and

projected revenues during the period of the payment adjustment; names

of purchasers; and other information we consider appropriate for making

a determination. Because of the revisions made to this process in the

final rule, interested parties will not be required to submit

information that is related to costs or sales as stated above. For a

further discussion of this issue, see the Analysis of and Responses to

Public Comments section.

Interested parties should be aware that 45 CFR 5.65(c) provides

that a

[[Page 32203]]

submitter of information may designate all or part of the information

as being exempt from mandatory disclosure under Exemption 4 of the

Freedom of Information Act.

III. Analysis of and Responses to Public Comments

We received 16 timely items of correspondence. The comments were

from ophthalmologists, professional organizations, IOL manufacturers,

and ASCs. A summary of the major issues and our responses follow:

Comment: Several commenters suggested that, in addition to using

FDA product labeling to identify what qualifies as a new technology

lens, we should also consider data from well-designed and controlled

health outcomes and economic studies through consultation with medical

and industry experts.

Response: As we stated in the proposed rule, we considered

convening an expert panel to evaluate claims of the clinical

superiority of an IOL. Because the expertise and review process already

exist within another Health and Human Services agency, namely the FDA,

it would be duplicative for us to convene such a panel of experts. We,

therefore, are not accepting this suggestion, and will rely on the FDA

approval process for labeling and advertising purposes to determine

that an IOL will be treated as a new technology lens.

Comment: Several commenters disagreed with the 2-year payment limit

on single model new technology IOLs and the 5-year limit on the

adjustment for subsets of new technology IOLs. The commenters thought

that the payment adjustment should be extended to 7 years.

Response: After carefully considering the arguments made by these

commenters, we believe we can resolve this issue with a compromise. We

will extend the payment limit for single model new technology IOLs to 5

years beginning with the date that we recognize this particular IOL as

a new technology IOL. Any subsequent IOL with the same characteristics

will receive the payment adjustment for the remainder of the 5-year

period established by the initial new technology IOL. For example, if

new technology IOL ``A'' is recognized to receive a payment adjustment

effective July 1, 1999, the payment adjustment would expire on June 30,

2004. The payment adjustment would then terminate, and revert back to

the standard IOL payment rate in effect at that time. If new technology

IOL ``B'' is recognized to receive a payment adjustment effective July

1, 2000, and has the same characteristics as ``A,'' the payment

adjustment for ``B'' would expire on June 30, 2004, and then revert

back to the IOL payment rate in effect at that time.

We realize that we cited the 1994 OIG report (Acquisition Costs of

Prosthetic Intraocular Lenses, OEI-05-92-01030), which found a decrease

in IOL prices generally over a 2-year period ranging from 11 to 14

percent in various settings. However, we believe that the initial

developer of a particular new technology lens should have some

advantage over subsequent developers of a similar lens, and

consequently we are extending the payment adjustment limit to 5 years

for those initial developers. We do not believe, however, that

extending the limit to 7 years is justified, given the data presented

in the above-mentioned OIG report.

Comment: One commenter disagreed with our view that the overall

statutory mandate would have precluded the adoption of a single flat

rate across-the-board percentage increase. That commenter indicated

that ``the new technology IOL enabling legislation provides no specific

guidance on the standard for judging the appropriateness of the current

IOL payment vis-a-vis the rate adjustment for the new technology IOL.

Given the fact that the purpose of the new technology IOL provision is

to facilitate beneficiary access to new IOL technology, we do not

believe the Congress would have intended HCFA to rely on historical

pricing data. With a new lens, there will be no history. Awaiting the

submission of acquisition data would delay the ability of providers to

purchase the products under current facility reimbursement

constraints.''

Response: In developing the process for adjusting payment rates for

new technology IOLs that we proposed in the September 4, 1997 Federal

Register, we rejected applying a single flat, across-the-board

percentage increase to the IOL payment amount for every IOL that we had

determined satisfied the definition of new technology IOLs (62 FR

46702). Initially, we rejected that approach, believing that it might

be viewed as inconsistent with a statutory requirement in section

1833(i)(2)(c) of the Act that the ASC allowance for IOLs be reasonable

and related to IOL acquisition costs. We have reconsidered our

interpretation in light of the public comment.

While it is true that section 141(b) of SSAA 1994 refers to section

1833(i)(2)(A)(iii) of the Act, the reference does not require the

conclusion that the amount of an adjustment for new technology IOLs

must also be reasonable and related to the cost of acquiring the IOL.

Indeed, the commenter's point is well taken that by focussing on the

clinical advantages of new technology IOLs, the Congress was attempting

to encourage beneficiary access to new technologies. The statutory

reference to section 1833(i)(2)(A)(iii) of the Act thus requires a

comparison of the clinical advantages of new technology to the standard

technology, and an adjustment to the payment rate to reflect the added

benefits of the new technology. It does not require a comparison of the

costs of acquiring standard IOLs to the costs of acquiring new

technology IOLs in determining the amount of any adjustment. We agree

that the statute can be reasonably interpreted to permit an adjustment

that is not related to the cost of acquiring the particular new

technology IOL. Since the flat rate adjustment for new technology IOLs

was one of the more frequently suggested comments, we have decided to

adopt this recommended approach.

Comment: Several commenters recommended that we develop a standard

payment rate that would apply to any lens that we find is in compliance

with the definition of a new technology IOL under the provisions of

this regulation. Commenters suggested as a new technology IOL premium

either a flat dollar amount between $50 and $75 or an amount equal to

between 30 percent and 50 percent of the allowance for a standard IOL.

One consequence of this approach would be to reduce the data

collection burden associated with our proposed requirement that

interested parties submit information related to manufacturing,

selling, overhead, and research and development costs, reducing the

burden for manufacturers. In other words, our determination that a lens

meets the criteria for being considered a new technology IOL would

alone be sufficient to trigger a payment adjustment. Several commenters

argued that the clinical outcomes resulting from use of the new

technology IOL so substantially exceed the outcomes expected from a

standard IOL as to justify payment of a premium. By definition, the

payment allowance for a standard IOL could not be appropriate for a new

technology IOL because the new technology IOL affords so many more

clinical advantages and outcomes than a standard IOL, and the new

technology IOL's additional features would not have been realized

without additional costs having been incurred.

Response: Having considered these comments, we have decided to

modify our original proposal and to adopt

[[Page 32204]]

instead payment of a flat, across-the-board $50 premium for any lens

for which a payment review is requested in accordance with the

provisions of the final regulations and that we find to comply with the

definition of a new technology IOL. We will adopt this $50 payment at

least until July 16, 2002.

During this 3-year period, we will monitor whether the flat payment

of $50 has provided beneficiaries access to new technology. We will

also monitor market parameters for IOLs. After this 3-year period, we

may adjust our payment rate for NTIOLs through proposed and final

rulemaking for ambulatory surgical centers.

The effect of adopting this approach will be to permit an expedited

consideration of a request for payment review, and a standard $50

payment adjustment for any lens that we determine is a new technology

IOL. We believe that a flat $50 premium per new technology IOL is a

reasonable amount and is enough to encourage manufacturers to continue

their IOL research and development programs. In fact, an industry-

sponsored study found that the use of a certain type of new technology

IOL, such as a multi-focal lens, enables a certain percentage of

cataract patients to forego Medicare-reimbursed post-cataract

eyeglasses. A payment adjustment of $50 for this type of lens seems to

be justified since it offers certain benefits to both the beneficiary

and the Medicare program. A flat rate adjustment also will expedite our

review process and gives Medicare beneficiaries quicker access to new

technology. By adopting a flat dollar amount, rather than a percentage

of the standard IOL allowance, we hold the premium constant against

potential increases or reductions in the IOL allowance for standard

lenses.

Comment: Several commenters stated that the application process is

cumbersome, time-consuming, and not possible due to the proprietary

nature of the information that will have to be supplied by IOL

manufacturers. Along the same line, several commenters thought that we

should make the adjusted payment amount available within 90 to 180

days.

Response: As discussed above, by adopting a flat rate payment

amount of $50, the time required for the application process would be

dramatically reduced. The payment adjustment amount could be

implemented within 180 days after receipt of the request to review a

new technology IOL.

The commenters were also concerned that due to the proprietary

nature of the information that would have to have been supplied,

businesses could be reluctant to submit the requested information. By

reducing the types of data necessary to make the determination, the

final rule should alleviate some of the public's concern. In addition,

as we stated in the proposed rule, 45 CFR 5.65(c) provides that a

submitter of information may designate all or part of the information

that he or she is submitting as being exempt from mandatory disclosure

under Exemption 4 of the Freedom of Information Act. We reiterate that

we will abide by the submitter's request if the submitter wishes any

information to be withheld from disclosure.

Comment: Two commenters requested that we provide for appeals of

our new technology IOL decisions.

Response: The SSAA 1994 does not require any appeal of this

determination. Moreover, section 1869 of the Act already provides

beneficiaries and certain other individuals the ability to challenge

the amount of benefits paid if a claim is denied. We do not believe

additional appeal rights are warranted and, therefore, are not

accepting this comment.

Comment: Two commenters thought that interested parties who request

a payment adjustment for new technology IOLS should be able to

demonstrate that the payment adjustment be continued past the time

limit.

Response: As discussed earlier in this section, we are increasing

the time limit for an adjusted payment from 2 years to 5 years for the

initial new technology IOL approved for the adjusted payment. Any

subsequent new technology IOL with the same characteristics as the

initial IOL will get the adjusted payment for the remainder of the 5-

year period. Given the data presented in the 1994 OIG report, we

believe this extension is sufficient to alleviate the need for a

demonstration to extend payment beyond this time period.

IV. Provisions of the Final Regulations

In response to the comments we received, we are making several

revisions to the proposed rule that we believe will streamline the

process for determining an appropriate payment amount for new

technology IOLS.

We are revising Sec. 416.185, ``Payment review process.'' In the

proposed rule, interested parties seeking an adjustment in the current

IOL payment rate for a new technology lens would have been required to

submit information related to manufacturing, selling, overhead,

research and development costs in addition to any other information

that would be considered appropriate in determining a payment

adjustment. In the final rule, we are eliminating the need for this

information to establish a payment adjustment. Instead, we are

establishing a flat rate adjustment of $50 over the current rate for

standard IOLs for 3 years beginning on July 16, 1999. After this 3-year

period, we may adjust our payment rate for IOLs through proposed and

final rulemaking for ambulatory surgical centers.

This change also has an impact on Sec. 416.195, ``A request to

review.'' In this section of the proposed rule, we were requiring

documented evidence of the cost of the IOL and the manufacturer's

investment in the IOL. This will no longer be necessary, since the

final rule establishes a flat rate payment adjustment.

Another revision to the proposed rule is Sec. 416.200,

``Application of the payment adjustment.'' In the proposed rule, a

single model IOL was recognized for a payment adjustment for a period

of 2 years. We have revised that provision to extend the payment

adjustment period to 5 years for the first IOL in a subset that we

approve for the payment adjustment. Any subsequent IOL with the same

characteristics as the first IOL recognized for a payment adjustment

would receive the adjustment for the remainder of the 5-year period

established by the first recognized IOL.

With these revisions to the proposed rule in place, we will then be

able to shorten the time it takes to complete the review process in

order to establish a payment adjustment. The proposed rule set up a

365-day cycle for the completion of this process. Although we are still

required to publish two Federal Register notices in this review

process, one with a 30-day comment period showing the list of requests

received, and another within 90 days after the close of the comment

period indicating the determinations that were made, we should be able

to decrease the time to 180 days.

Finally, this rule will serve as the initial notice to those

wishing to submit requests for review of the appropriateness of the

payment amount with respect to a particular IOL, in accordance with

Sec. 416.195 of this rule. We will accept requests for 60 days

following the effective date of this regulation. Subsequent requests

for review of payment amounts will be made in accordance with the

regulations as stated in this final rule. Please submit requests to:

Grant Bagley, M.D., Director, Coverage and Analysis Group, Office of

Clinical Standards and Quality, S3-02-01, 7500 Security Boulevard,

Baltimore, Maryland 21244.

[[Page 32205]]

V. Collection of Information Requirements

Under the Paperwork Reduction Act (PRA) of 1995, we are required to

provide 60-day notice in the Federal Register and solicit public

comment before a collection of information requirement is submitted to

the Office of Management and Budget (OMB) for review and approval. In

order to fairly evaluate whether an information collection should be

approved by OMB, section 3506(c)(2)(A) of the PRA of 1995 requires that

we solicit comment on the following issues:

The need for the information collection and its usefulness

in carrying out the proper functions of our agency.

The accuracy of our estimate of the information collection

burden.

The quality, utility, and clarity of the information to be

collected.

Recommendations to minimize the information collection

burden on the affected public, including automated collection

techniques.

Therefore, we are soliciting public comment on the information

collection requirement discussed below.

Section 416.195 A Request To Review

Section 416.195(a) states that the request must include all of the

following information:

(1) The name of the manufacturer, the model number, and the trade

name of the IOL.

(2) A copy of the FDA's summary of the IOL's safety and

effectiveness.

(3) A copy of the labeling claims of specific clinical advantages

approved by the FDA for the IOL.

(4) A copy of the IOL's original FDA approval notification.

(5) Reports of modifications made subsequent to original FDA

approval.

(6) Other information that HCFA finds necessary for identification

of the IOL.

We believe the above requirement is not subject to the Act in

accordance with 5 CFR 1320.3(c)(4) since this requirement does not

collect information from 10 or more entities on an annual basis.

We have submitted a copy of this final rule to OMB for its review

of the information collection requirements described above.

If you comment on any of these information collection and

recordkeeping requirements, please mail copies directly to the

following:

Health Care Financing Administration, Office of Information Services,

Security and Standards Group, Division of HCFA Enterprise Standards,

Room N2-14-26, 7500 Security Boulevard, Baltimore, MD 21244-1850, ATTN:

Louis Blank, HCFA-3831-F

and

Office of Information and Regulatory Affairs, Office of Management and

Budget, Room 10235, New Executive Office Building, Washington, DC

20503, Attn: Allison Eydt, HCFA Desk Officer

VI. Regulatory Impact Statement

We generally prepare a regulatory flexibility analysis that is

consistent with the Regulatory Flexibility Act (RFA) (5. U.S.C. 601

through 612) unless the Secretary certifies that a rule not have a

significant economic impact on a substantial number of small entities.

For purposes of the RFA, we consider all manufacturers of IOLs, ASCs,

hospital outpatient departments, and physicians who perform IOL

insertion surgery to be small entities. Individuals and States are not

included in the definitions of a small entity. We are not preparing a

regulatory flexibility analysis because we have determined, and the

Secretary certifies, that this regulation will not have a significant

economic impact on a substantial number of small entities.

Also, section 1102(b) of the Act requires the Secretary to prepare

a regulatory impact analysis if a rule will have a significant impact

on the operations of a substantial number of small rural hospitals.

This analysis must conform to the provisions of section 604 of the RFA.

For purposes of section 1102(b) of the Act, we define a small rural

hospital as a hospital that is located outside of a Metropolitan

Statistical Area and has fewer than 50 beds. We are not preparing a

rural hospital impact statement because we have determined, and the

Secretary certifies, that this regulation will not have a significant

impact on the operations of a substantial number of small rural

hospitals.

Although this rule is not an ``economically significant'' rule

under Executive Order 12866, we present below a voluntary analysis of

the effects of this rule because many beneficiaries who undergo IOL

insertion surgery following a cataract extraction could be affected.

We believe that the fiscal impact of this rule will be negligible.

We do not expect that making this payment adjustment will have an

impact on the availability or prices of other IOLs. We do not expect

that is will affect competition, employment, or investment. The ocular

implant industry is mature, with a successful product readily available

to purchasers. Our data suggest that we pay, under the Medicare

program, more than the acquisition cost for most of the IOLs used

today. In our June 12, 1998 proposed rule, ``Medicare Program; Update

of Ratesetting Methodology, Payment Rates, Payment Policies, and the

List of Covered Surgical Procedures for Ambulatory Surgical Centers

Effective October 1, 1998'' (63 FR 32303), we stated that we would be

proposing a new payment amount for the standard IOL that reflects the

cost of acquiring the lens. New technology IOLs will achieve

improvements in only small segments of the industry, since the majority

of IOLs function superbly. The IOLs under development that we are aware

of will substitute for spectacles in some cases, and in others will

allow the patient to wear a single vision prescription rather than

bifocals.

In accordance with the provisions of Executive Order 12866, this

regulation was reviewed by the Office of Management and Budget.

List of Subjects in 42 CFR Part 416

Health facilities, Kidney diseases, Medicare, Reporting and

recordkeeping requirements.

For the reasons set forth in the preamble, 42 CFR part 416 is

amended as follows:

PART 416--AMBULATORY SURGICAL SERVICES

1. The authority citation for part 416 continues to read as

follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42

U.S.C. 1302 and 1395hh).

2. A new subpart F, consisting of Secs. 416.180, 416.185, 416.190,

416.195, and 416.200, is added to read as follows:

Subpart F--Adjustment in Payment Amounts for New Technology Intraocular

Lenses Furnished by Ambulatory Surgical Centers

Sec.

416.180 Definitions.

416.185 Payment review process.

416.190 Who may request a review.

416.195 A request to review.

416.200 Application of the payment adjustment.

Subpart F--Adjustment in Payment Amounts for New Technology

Intraocular Lenses Furnished by Ambulatory Surgical Centers

Sec. 416.180 Definitions.

As used in this subpart, the following definitions apply:

Class of new technology intraocular lenses (IOLs) means all of the

IOLs, collectively, that HCFA determines meet the definition of ``new

technology IOL'' under the provisions of this subpart.

[[Page 32206]]

Interested party means any individual, partnership, corporation,

association, society, scientific or academic establishment,

professional or trade organization, or any other legal entity.

New technology IOL means an IOL that HCFA determines has been

approved by the FDA for use in labeling and advertising the IOL's

claims of specific clinical advantages and superiority over existing

IOLs with regard to reduced risk of intraoperative or postoperative

complication or trauma, accelerated postoperative recovery, reduced

induced astigmatism, improved postoperative visual acuity, more stable

postoperative vision, or other comparable clinical advantages.

New technology subset means a group of IOLs that HCFA determines

meet the criterion for being treated as new technology IOLs and that

share a common feature or features that distinguish them from other

IOLs. For example, all new technology IOLs that are made of a

particular bioengineered material could comprise one subset, while all

that rely on a particular optical innovation could comprise another.

Sec. 416.185 Payment review process.

(a) HCFA publishes a Federal Register notice announcing the

deadline and requirements for submitting a request for HCFA to review

payment for an IOL.

(b) HCFA receives a request to review the appropriateness of the

payment amount for an IOL.

(c) HCFA compiles a list of the requests it receives and identifies

the IOL manufacturer's name, the model number of the IOL to be

reviewed, the interested party or parties that submit requests, and a

summary of the interested party's grounds for requesting review of the

appropriateness of the IOL payment amount.

(d) HCFA publishes the list of requests in a Federal Register

notice with comment period, giving the public 30 days to comment on the

IOLs for which review was requested.

(e) HCFA reviews the information submitted with the request to

review, any timely public comments that are submitted regarding the

list of IOLs published in the Federal Register, and any other timely

information that HCFA deems relevant to decide whether to provide a

payment adjustment as specified in Sec. 416.200. HCFA makes a

determination of whether the IOL meets the definition of a new

technology IOL in Sec. 416.180.

(f) If HCFA determines that a lens is a new technology IOL, HCFA

establishes a payment adjustment as follows:

(1) Before July 16, 2002--$50.

(2) After July 16, 2002--$50 or the amount announced through

proposed and final rulemaking in connection with ambulatory surgical

center services.

(g) HCFA designates a predominant characteristic of a new

technology IOL that both sets it apart from other IOLs and links it

with other similar IOLs with the same characteristic to establish a

specific subset of new technology within the ``class of new technology

IOLs.''

(h) Within 90 days of the end of the comment period following the

Federal Register notice identified in paragraph (d) of this section,

HCFA publishes in the Federal Register its determinations with regard

to IOLs that it has determined are ``new technology'' lenses that

qualify for a payment adjustment.

(i) Payment adjustments are effective beginning 30 days after the

publication of HCFA's determinations in the Federal Register.

Sec. 416.190 Who may request a review.

Any party who is able to furnish the information required in

Sec. 416.195 may request that HCFA review the appropriateness of the

payment amount provided under section 1833(i)(2)(A)(iii) of the Act

with respect to an IOL that meets the definition of a new technology

IOL in Sec. 416.180.

Sec. 416.195 A request to review.

(a) Content of a request. The request must include all of the

following information:

(1) The name of the manufacturer, the model number, and the trade

name of the IOL.

(2) A copy of the FDA's summary of the IOL's safety and

effectiveness.

(3) A copy of the labeling claims of specific clinical advantages

approved by the FDA for the IOL.

(4) A copy of the IOL's original FDA approval notification.

(5) Reports of modifications made after the original FDA approval.

(6) Other information that HCFA finds necessary for identification

of the IOL.

(b) Confidential information. To the extent that information

received from an IOL manufacturer can reasonably be characterized as a

trade secret or as privileged or confidential commercial or financial

information, HCFA maintains the confidentiality of the information and

protects it from disclosure not otherwise authorized or required by

Federal law as allowed under Exemption 4 of the Freedom of Information

Act (5 U.S.C. 552(b)(4)) and, with respect to trade secrets, the Trade

Secrets Act (18 U.S.C. 1905).

Sec. 416.200 Application of the payment adjustment.

(a) HCFA recognizes the IOL(s) that define a new technology subset

for purposes of this subpart as belonging to the class of new

technology IOLs for a period of 5 years effective from the date that

HCFA recognizes the first new technology IOL for a payment adjustment.

(b) Any IOL that HCFA subsequently recognizes as belonging to a new

technology subset receives the new technology payment adjustment for

the remainder of the 5-year period established with HCFA's recognition

of the first IOL in the subset.

(c) Beginning 5 years after the effective date of HCFA's initial

recognition of a new technology subset, payment adjustments cease for

all IOLs that HCFA designates as belonging to that subset and payment

reverts to the standard payment rate set under section

1833(i)(2)(A)(iii) of the Act for IOL insertion procedures performed in

ASCs.

(d) ASCs that furnish an IOL designated by HCFA as belonging to the

class of new technology IOLs must submit claims using specific billing

codes to receive the new technology IOL payment adjustment.

(Sections 1832(a)(2)(F)(i) and 1833(i)(2)(a) of the Social Security

Act (42 U.S.C. 1395k(a)(2)(F)(i) and 1395l(i)(2)(a)))

(Catalog of Federal Domestic Assistance Program No. 93.774,

Medicare--Supplementary Medical Insurance Program)

Dated: January 15, 1999.

Nancy-Ann Min DeParle,

Administrator, Health Care Financing Administration.

Dated: March 8, 1999.

Donna E. Shalala,

Secretary.

[FR Doc. 99-15067 Filed 6-14-99; 8:45 am]

BILLING CODE 4120-01-P

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.